Neuralstem in the News
UCSD Looking For Spinal Cord Injury Patients To Test Stem Cell Treatment
San Diego Public Radio & TV put out the call on behalf of the UC San Diego Health Center for spinal cord injury patients to take part in Neuralstem's FDA-approved NSI-566/cSCI Phase I trial. The injury must have occurred between one and two years ago, and be between the 7th and 12th thoracic vertebrae. UCSD's Dr. Joseph Ciacci, the study's principal investigator, is quoted and Dr. Ciacci's and Dr. Martin Marsala's research work, which "detected signs of improved motor function with minimal side effects" was cited, as were the cells' safety proven in Neuralstem's ALS trials.
Clinical trial to investigate safety of neural stem cell transplantation in patients with spinal cord injuries
Global online medical and health news service reports on UCSD researchers launching the NSI-566/cSCI clinical trial and recruiting patients. In addition to evaluating the stem cell graft's survival and the effectiveness of immunosuppression drugs to prevent rejection, the article notes that the researchers will look for therapeutic benefits such as changes in motor and sensory function, bowel and bladder function, and pain levels.
Excerpts from Tom Henderson’s Interview with Dr. Eva Feldman
Neuralstem’s NSI-566/ALS Principal Investigator Eva L. Feldman, MD, PhD, shares that she is continuing tests of the 15 patients in the Phase II trial to determine how the injection of the neural stem cells slows down the progression of the disease. She states that she hopes to begin the next phase of the trials, which will involve 32 ALS patients, in the first quarter of 2015. Dr. Feldman went on to say that her results from just-concluded animal research injecting 50,000 stem cells into a line of mice that have inherited genes for Alzheimer’s disease has exceeded her expectations. “I’m so geeked about this…. We’ve never seen data like this. They’ve (the mice) have essentially gone back to normal,” Dr. Feldman said. She is awaiting word from the FDA on which large mammal to use in the next set of Alzheimer’s tests. “If everything goes well, in a year from now we can be talking about clinical trials on humans,” she told Crain’s Tom Henderson.
Researchers Fret as Social Media Lift Veil on Drug Trials
Neuralstem’s President and CEO, Richard Garr, is interviewed in this front-page feature story that examines patient-directed social media’s impact on blinded clinical trials. While Neuralstem’s NSI-566 cell therapy trials have not been blinded, ALS patients have independently chosen to blog online or speak publicly about their treatments during the trials which represent the first FDA-approved neural stem cell clinical trials for the treatment of ALS, with Phase I begun in 2010 and the Phase II surgeries of the final cohort nearly concluded.
Neurogenic Drug Improves Depression in Small Trial
Science Editor Cynthia Fox issued a report on first-in-class neurogenic NSI-189/major depressive disorder (MDD) Phase I data, presented by Mass Gen/Harvard’s Dr. Marlene Freeman, at ASCP’s annual meeting. She reports that “depressed patients taking two different doses of the drug have now experienced a ‘clinically meaningful’ relief of depressive and cognitive symptoms across all measures in comparison to placebo. This relief continued throughout the follow-up period,” which was for two months following the 28-day dosing. Neuralstem’s President and CEO, Richard Garr, is quoted as saying, “this is a very solid sign pointing to confirming our thesis that what we see in animals—structurally rebuilding the hippocampus—is also happening in humans.”
- ALS Breakthrough Involves Rhode Island Patient
- Neuralstem could seek partner for Phase II depression small molecule; to develop stem cell therapy solo – CEO
- New trial may be step forward for spinal cord injuries
- Neuralstem doses ischemic stroke patient with stem cells directly into the brain
- Stem cell trial seeks longer lives for victims of deadly ALS
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.